Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016 (2016), Article ID 6430423, 9 pages
http://dx.doi.org/10.1155/2016/6430423
Review Article

The Emerging Role of HMGB1 in Neuropathic Pain: A Potential Therapeutic Target for Neuroinflammation

1Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
2State Key Laboratory of Medical Neurobiology, Department of Neurobiology and Institutes of Brain Science, School of Basic Medical Science, Fudan University, Shanghai 200032, China
3Department of Maternal-Fetal Medicine, Pregnancy Research Centre and Department of Obstetrics and Gynaecology, Royal Women’s Hospital, University of Melbourne, Parkville, VIC 3052, Australia
4School of Acupuncture, Massage and Rehabilitation, Yunnan University of Traditional Chinese Medicine, Kunming 650500, China
5Shanghai Institute of Geriatrics, Huadong Hospital, Fudan University, Shanghai 200040, China

Received 16 February 2016; Accepted 26 April 2016

Academic Editor: Moisés E. Bauer

Copyright © 2016 Wenbin Wan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Yalcin, F. Barthas, and M. Barrot, “Emotional consequences of neuropathic pain: insight from preclinical studies,” Neuroscience and Biobehavioral Reviews, vol. 47, pp. 154–164, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Maeda, M. Ozaki, Y. Kobayashi, N. Kiguchi, and S. Kishioka, “HMGB1 as a potential therapeutic target for neuropathic pain,” Journal of Pharmacological Sciences, vol. 123, no. 4, pp. 301–305, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Collins, M. J. Sigtermans, A. Dahan, W. W. A. Zuurmond, and R. S. G. M. Perez, “NMDA receptor antagonists for the treatment of neuropathic pain,” Pain Medicine, vol. 11, no. 11, pp. 1726–1742, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Baron, “Mechanisms of disease: neuropathic pain—a clinical perspective,” Nature Clinical Practice Neurology, vol. 2, no. 2, pp. 95–106, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. I. Gilron and A. H. Dickenson, “Emerging drugs for neuropathic pain,” Expert Opinion on Emerging Drugs, vol. 19, no. 3, pp. 329–341, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Attal, M. Lanteri-Minet, B. Laurent, J. Fermanian, and D. Bouhassira, “The specific disease burden of neuropathic pain: results of a French nationwide survey,” Pain, vol. 152, no. 12, pp. 2836–2843, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Schaefer, A. Sadosky, R. Mann et al., “Pain severity and the economic burden of neuropathic pain in the United States: BEAT Neuropathic Pain Observational Study,” ClinicoEconomics and Outcomes Research, vol. 6, pp. 483–496, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Szczudlik, J. Dobrogowski, J. Wordliczek et al., “Diagnosis and management of neuropathic pain: review of literature and recommendations of the Polish Association for the study of pain and the Polish Neurological Society—part one,” Neurologia i Neurochirurgia Polska, vol. 48, no. 4, pp. 262–271, 2014. View at Google Scholar
  9. J. H. Vranken, “Elucidation of pathophysiology and treatment of neuropathic pain,” Central Nervous System Agents in Medicinal Chemistry, vol. 12, no. 4, pp. 304–314, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. E. K. Krumova, C. Geber, A. Westermann, and C. Maier, “Neuropathic pain: is quantitative sensory testing helpful?” Current Diabetes Reports, vol. 12, no. 4, pp. 393–402, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Brod, B. Pohlman, S. I. Blum, A. Ramasamy, and R. Carson, “Burden of illness of diabetic peripheral neuropathic pain: a qualitative study,” Patient, vol. 8, no. 4, pp. 339–348, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Pereira, F. Fontes, T. Sonin et al., “Neurological complications of breast cancer: study protocol of a prospective cohort study,” BMJ Open, vol. 4, no. 10, Article ID e006301, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Attal, C. Fermanian, J. Fermanian, M. Lanteri-Minet, H. Alchaar, and D. Bouhassira, “Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion?” Pain, vol. 138, no. 2, pp. 343–353, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. V. Erthal and P. Nohama, “Treatment for neuropathic pain and chronic inflammation using LASER in animal models,” in Proceedings of the 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC '15), pp. 1315–1318, Milan, Italy, August 2015. View at Publisher · View at Google Scholar
  15. Y. Kobayashi, N. Kiguchi, Y. Fukazawa, F. Saika, T. Maeda, and S. Kishioka, “Macrophage-T cell interactions mediate neuropathic pain through the glucocorticoid-induced tumor necrosis factor ligand system,” The Journal of Biological Chemistry, vol. 290, no. 20, pp. 12603–12613, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. L. H. Hang, S. N. Li, H. Luo et al., “Connexin 43 mediates CXCL12 production from spinal dorsal horn to maintain bone cancer pain in Rats,” Neurochemical Research, vol. 41, no. 5, pp. 1200–1208, 2016. View at Publisher · View at Google Scholar
  17. L. Vas and R. Pai, “Reversal of complex regional pain syndrome type 2 and the subsequent management of complex regional pain syndrome type 1 occurring after corrective surgery for residual ulnar claw,” Pain Medicine, vol. 15, no. 6, pp. 1059–1063, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Afsharimani, K. Kindl, P. Good, and J. Hardy, “Pharmacological options for the management of refractory cancer pain—what is the evidence?” Supportive Care in Cancer, vol. 23, no. 5, pp. 1473–1481, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. X. Kuang, Y. Huang, H.-F. Gu et al., “Effects of intrathecal epigallocatechin gallate, an inhibitor of Toll-like receptor 4, on chronic neuropathic pain in rats,” European Journal of Pharmacology, vol. 676, no. 1–3, pp. 51–56, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. C. R. Jutzeler, E. Huber, M. F. Callaghan et al., “Association of pain and CNS structural changes after spinal cord injury,” Scientific Reports, vol. 6, Article ID 18534, 2016. View at Publisher · View at Google Scholar
  21. Y. Chen, X. Chen, J. Yu et al., “JAB1 is involved in neuropathic pain by regulating JNK and NF-κB activation after chronic constriction injury,” Neurochemical Research, vol. 41, no. 5, pp. 1119–1129, 2016. View at Publisher · View at Google Scholar
  22. S. Wang, H. Xu, L. Zou et al., “LncRNA uc.48+ is involved in diabetic neuropathic pain mediated by the P2X3 receptor in the dorsal root ganglia,” Purinergic Signalling, vol. 12, no. 1, pp. 139–148, 2016. View at Publisher · View at Google Scholar
  23. A. Taheri, A. Farbood, R. Heshmat et al., “The effect of transdermal nitroglycerin on pain control in diabetic patients with peripheral neuropathy,” Journal of Diabetes & Metabolic Disorders, vol. 14, article 86, 2015. View at Publisher · View at Google Scholar
  24. G. W. Jay and R. L. Barkin, “Neuropathic pain: etiology, pathophysiology, mechanisms, and evaluations,” Disease-a-Month, vol. 60, no. 1, pp. 6–47, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. U. Andersson and K. J. Tracey, “HMGB1 is a therapeutic target for sterile inflammation and infection,” Annual Review of Immunology, vol. 29, pp. 139–162, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. G. H. Goodwin, C. Sanders, and E. W. Johns, “A new group of chromatin associated proteins with a high content of acidic and basic amino acids,” European Journal of Biochemistry, vol. 38, no. 1, pp. 14–19, 1973. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Kang, R. Chen, Q. Zhang et al., “HMGB1 in health and disease,” Molecular Aspects of Medicine, vol. 40, pp. 1–116, 2014. View at Google Scholar
  28. B. Holland, “Revised nomenclature for high mobility group (HMG) chromosomal proteins,” Trends in Biochemical Sciences, vol. 26, no. 3, pp. 152–153, 2001. View at Google Scholar · View at Scopus
  29. K. Peter and A. Bobik, “HMGB1 signals danger in acute coronary syndrome: emergence of a new risk marker for cardiovascular death?” Atherosclerosis, vol. 221, no. 2, pp. 317–318, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. H. M. Weir, P. J. Kraulis, C. S. Hill, A. R. C. Raine, E. D. Laue, and J. O. Thomas, “Structure of the HMG box motif in the B-domain of HMG1,” The EMBO Journal, vol. 12, no. 4, pp. 1311–1319, 1993. View at Google Scholar · View at Scopus
  31. T. B. Lin, M. C. Hsieh, C. Y. Lai et al., “Melatonin relieves neuropathic allodynia through spinal MT2-enhanced PP2Ac and downstream HDAC4 shuttling-dependent epigenetic modification of hmgb1 transcription,” Journal of Pineal Research, vol. 60, no. 3, pp. 263–276, 2016. View at Publisher · View at Google Scholar
  32. M. Magna and D. S. Pisetsky, “The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases,” Molecular Medicine, vol. 20, no. 1, pp. 138–146, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Yang, P. Lundbäck, L. Ottosson et al., “Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1),” Molecular Medicine, vol. 18, no. 2, pp. 250–259, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Zhu, G. Huang, J. Sheng, Q. Fu, and A. Chen, “High-mobility group box 1 induces neuron autophagy in a rat spinal root avulsion model,” Neuroscience, vol. 315, pp. 286–295, 2016. View at Publisher · View at Google Scholar
  35. Y. Liu, R. Prasad, and S. H. Wilson, “HMGB1: roles in base excision repair and related function,” Biochimica et Biophysica Acta, vol. 1799, no. 1-2, pp. 119–130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Raucci, R. Palumbo, and M. E. Bianchi, “HMGB1: a signal of necrosis,” Autoimmunity, vol. 40, no. 4, pp. 285–289, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. J. K. Juranek, G. K. Daffu, J. Wojtkiewicz, D. Lacomis, J. Kofler, and A. M. Schmidt, “Receptor for advanced glycation end products and its inflammatory ligands are upregulated in amyotrophic lateral sclerosis,” Frontiers in Cellular Neuroscience, vol. 9, article 485, 2015. View at Publisher · View at Google Scholar
  38. P. Castellani, E. Balza, and A. Rubartelli, “Inflammation, DAMPs, tumor development, and progression: a vicious circle orchestrated by redox signaling,” Antioxidants and Redox Signaling, vol. 20, no. 7, pp. 1086–1097, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Tang, X. Zhao, D. Antoine et al., “Regulation of post-translational modifications of HMGB1 during immune responses,” Antioxidants & Redox Signaling, vol. 24, no. 12, pp. 620–634, 2016. View at Publisher · View at Google Scholar
  40. N. M. Agalave and C. I. Svensson, “Extracellular high-mobility group box 1 protein (HMGB1) as a mediator of persistent pain,” Molecular Medicine, vol. 20, no. 1, pp. 569–578, 2015. View at Google Scholar
  41. G. Basta, “Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications,” Atherosclerosis, vol. 196, no. 1, pp. 9–21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. M. Allette, M. R. Due, S. M. Wilson et al., “Identification of a functional interaction of HMGB1 with Receptor for Advanced Glycation End-products in a model of neuropathic pain,” Brain, Behavior, and Immunity, vol. 42, pp. 169–177, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. W. K. den Dekker, C. Cheng, G. Pasterkamp, and H. J. Duckers, “Toll like receptor 4 in atherosclerosis and plaque destabilization,” Atherosclerosis, vol. 209, no. 2, pp. 314–320, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. Y.-Q. Ma, Y.-R. Chen, Y.-F. Leng, and Z.-W. Wu, “Tanshinone IIA downregulates HMGB1 and TLR4 expression in a spinal nerve ligation model of neuropathic pain,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 639563, 8 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. Liu, W. Yan, S. Tohme et al., “Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9,” Journal of Hepatology, vol. 63, no. 1, article no. 5550, pp. 114–121, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Friggeri, Y. Yang, S. Banerjee, Y.-J. Park, G. Liu, and E. Abraham, “HMGB1 inhibits macrophage activity in efferocytosis through binding to the αvβ3-integrin,” American Journal of Physiology—Cell Physiology, vol. 299, no. 6, pp. C1267–C1276, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. J.-X. Song, J.-H. Lu, L.-F. Liu et al., “HMGB1 is involved in autophagy inhibition caused by SNCA/α-synuclein overexpression: a process modulated by the natural autophagy inducer corynoxine B,” Autophagy, vol. 10, no. 1, pp. 144–154, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. T. S. Kim, S. A. Gorski, S. Hahn, K. M. Murphy, and T. J. Braciale, “Distinct dendritic cell subsets dictate the fate decision between effector and memory CD8+ T cell differentiation by a CD24-dependent mechanism,” Immunity, vol. 40, no. 3, pp. 400–413, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Balosso, J. Liu, M. E. Bianchi, and A. Vezzani, “Disulfide-containing high mobility group box-1 promotes N-methyl-d-aspartate receptor function and excitotoxicity by activating toll-like receptor 4-dependent signaling in hippocampal neurons,” Antioxidants and Redox Signaling, vol. 21, no. 12, pp. 1726–1740, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Yang, Q. Chen, H. Yang, K. J. Tracey, M. Bustin, and J. J. Oppenheim, “High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin,” Journal of Leukocyte Biology, vol. 81, no. 1, pp. 59–66, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Yang, P. Tewary, G. de la Rosa, F. Wei, and J. J. Oppenheim, “The alarmin functions of high-mobility group proteins,” Biochimica et Biophysica Acta—Gene Regulatory Mechanisms, vol. 1799, no. 1-2, pp. 157–163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Vezzoli, P. Castellani, L. Campana et al., “Redox remodeling: a candidate regulator of HMGB1 function in injured skeletal muscle,” Annals of the New York Academy of Sciences, vol. 1209, no. 1, pp. 83–90, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Chacur, E. D. Milligan, L. S. Gazda et al., “A new model of sciatic inflammatory neuritis (SIN): induction of unilateral and bilateral mechanical allodynia following acute unilateral peri-sciatic immune activation in rats,” Pain, vol. 94, no. 3, pp. 231–244, 2001. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Tanaka, Y. Seki, H. Ishikura et al., “Recombinant human soluble thrombomodulin prevents peripheral HMGB1-dependent hyperalgesia in rats,” British Journal of Pharmacology, vol. 170, no. 6, pp. 1233–1241, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Vezzani, M. Maroso, S. Balosso, M.-A. Sanchez, and T. Bartfai, “IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures,” Brain, Behavior, and Immunity, vol. 25, no. 7, pp. 1281–1289, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Zhang, H. Zhang, and T. Zi, “Overexpression of microRNA-141 relieves chronic constriction injury-induced neuropathic pain via targeting high-mobility group box 1,” International Journal of Molecular Medicine, vol. 36, no. 5, pp. 1433–1439, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Shibasaki, M. Sasaki, M. Miura et al., “Induction of high mobility group box-1 in dorsal root ganglion contributes to pain hypersensitivity after peripheral nerve injury,” Pain, vol. 149, no. 3, pp. 514–521, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. F. F. Zhang, N. Morioka, S. Harano et al., “Perineural expression of high-mobility group box-1 contributes to long-lasting mechanical hypersensitivity via matrix metalloprotease-9 up-regulation in mice with painful peripheral neuropathy,” Journal of Neurochemistry, vol. 136, no. 4, pp. 837–850, 2016. View at Publisher · View at Google Scholar
  59. H. S. Hreggvidsdóttir, A. M. Lundberg, A.-C. Aveberger, L. Klevenvall, U. Andersson, and H. E. Harris, “High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor,” Molecular Medicine, vol. 18, no. 2, pp. 224–230, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. L. Campana, L. Bosurgi, M. E. Bianchi, A. A. Manfredi, and P. Rovere-Querini, “Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells,” Journal of Leukocyte Biology, vol. 86, no. 3, pp. 609–615, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. K.-I. Otoshi, S.-I. Kikuchi, K. Kato, M. Sekiguchi, and S.-I. Konno, “Anti-HMGB1 neutralization antibody improves pain-related behavior induced by application of autologous nucleus pulposus onto nerve roots in rats,” Spine, vol. 36, no. 11, pp. E692–E698, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. N. M. Agalave, M. Larsson, S. Abdelmoaty et al., “Spinal HMGB1 induces TLR4-mediated long-lasting hypersensitivity and glial activation and regulates pain-like behavior in experimental arthritis,” Pain, vol. 155, no. 9, pp. 1802–1813, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. Nakamura, N. Morioka, H. Abe et al., “Neuropathic pain in rats with a partial sciatic nerve ligation is alleviated by intravenous injection of monoclonal antibody to high mobility group box-1,” PLoS ONE, vol. 8, no. 8, Article ID e73640, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Tanaka, K. Yamaguchi, H. Ishikura et al., “Bladder pain relief by HMGB1 neutralization and soluble thrombomodulin in mice with cyclophosphamide-induced cystitis,” Neuropharmacology, vol. 79, pp. 112–118, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. P.-C. Ren, Y. Zhang, X.-D. Zhang et al., “High-mobility group box 1 contributes to mechanical allodynia and spinal astrocytic activation in a mouse model of type 2 diabetes,” Brain Research Bulletin, vol. 88, no. 4, pp. 332–337, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. R. J. Deane, “Is RAGE still a therapeutic target for Alzheimers disease?” Future Medicinal Chemistry, vol. 4, no. 7, pp. 915–925, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. R. Deane, I. Singh, A. P. Sagare et al., “A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease,” The Journal of Clinical Investigation, vol. 122, no. 4, pp. 1377–1392, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. W.-B. Wan, L. Cao, L.-M. Liu et al., “EGb761 provides a protective effect against Aβ1-42 oligomer-induced cell damage and blood-brain barrier disruption in an in vitro bEnd.3 endothelial model,” PLoS ONE, vol. 9, no. 11, Article ID 0113126, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. G. Fritz, “RAGE: a single receptor fits multiple ligands,” Trends in Biochemical Sciences, vol. 36, no. 12, pp. 625–632, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. W. Wan, L. Cao, L. Liu et al., “Aβ1−42oligomer-induced leakage in an in vitro blood-brain barrier model is associated with up-regulation of RAGE and metalloproteinases, and down-regulation of tight junction scaffold proteins,” Journal of Neurochemistry, vol. 134, no. 2, pp. 382–393, 2015. View at Publisher · View at Google Scholar · View at Scopus
  71. R. Ray, J. K. Juranek, and V. Rai, “RAGE axis in neuroinflammation, neurodegeneration and its emerging role in the pathogenesis of amyotrophic lateral sclerosis,” Neuroscience & Biobehavioral Reviews, vol. 62, pp. 48–55, 2016. View at Publisher · View at Google Scholar
  72. D. Musumeci, G. N. Roviello, and D. Montesarchio, “An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies,” Pharmacology and Therapeutics, vol. 141, no. 3, pp. 347–357, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. R. Kokkola, Å. Andersson, G. Mullins et al., “RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages,” Scandinavian Journal of Immunology, vol. 61, no. 1, pp. 1–9, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. W. Huang, Y. Liu, L. Li et al., “HMGB1 increases permeability of the endothelial cell monolayer via RAGE and Src family tyrosine kinase pathways,” Inflammation, vol. 35, no. 1, pp. 350–362, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. P. M. LeBlanc, T. A. Doggett, J. Choi et al., “An immunogenic peptide in the A-box of HMGB1 protein reverses apoptosis-induced tolerance through RAGE receptor,” The Journal of Biological Chemistry, vol. 289, no. 11, pp. 7777–7786, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. X. Wu, Y. Mi, H. Yang, A. Hu, Q. Zhang, and C. Shang, “The activation of HMGB1 as a progression factor on inflammation response in normal human bronchial epithelial cells through RAGE/JNK/NF-κB pathway,” Molecular and Cellular Biochemistry, vol. 380, no. 1-2, pp. 249–257, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. V. Iori, M. Maroso, M. Rizzi et al., “Receptor for Advanced Glycation Endproducts is upregulated in temporal lobe epilepsy and contributes to experimental seizures,” Neurobiology of Disease, vol. 58, pp. 102–114, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. Y. Okuma, K. Liu, H. Wake et al., “Glycyrrhizin inhibits traumatic brain injury by reducing HMGB1-RAGE interaction,” Neuropharmacology, vol. 85, pp. 18–26, 2014. View at Publisher · View at Google Scholar · View at Scopus
  79. M. B. Manigrasso, J. Juranek, R. Ramasamy, and A. M. Schmidt, “Unlocking the biology of RAGE in diabetic microvascular complications,” Trends in Endocrinology and Metabolism, vol. 25, no. 1, pp. 15–22, 2014. View at Publisher · View at Google Scholar · View at Scopus
  80. V. Meneghini, V. Bortolotto, M. T. Francese et al., “High-mobility group box-1 protein and β-amyloid oligomers promote neuronal differentiation of adult hippocampal neural progenitors via receptor for advanced glycation end products/nuclear factor-κβ Axis: relevance for Alzheimer's disease,” The Journal of Neuroscience, vol. 33, no. 14, pp. 6047–6059, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. B. Liliensiek, M. A. Weigand, A. Bierhaus et al., “Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response,” The Journal of Clinical Investigation, vol. 113, no. 11, pp. 1641–1650, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. T. Kawasaki and T. Kawai, “Toll-like receptor signaling pathways,” Frontiers in Immunology, vol. 5, article 461, 2014. View at Publisher · View at Google Scholar · View at Scopus
  83. T. Kawai and S. Akira, “The role of pattern-recognition receptors in innate immunity: update on toll-like receptors,” Nature Immunology, vol. 11, no. 5, pp. 373–384, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. T. Celhar, R. Magalhães, and A.-M. Fairhurst, “TLR7 and TLR9 in SLE: when sensing self goes wrong,” Immunologic Research, vol. 53, no. 1–3, pp. 58–77, 2012. View at Publisher · View at Google Scholar · View at Scopus
  85. Y. Xi, F. Shao, X.-Y. Bai, G. Cai, Y. Lv, and X. Chen, “Changes in the expression of the toll-like receptor system in the aging rat kidneys,” PLoS ONE, vol. 9, no. 5, Article ID e96351, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. T. Liu, Y.-J. Gao, and R.-R. Ji, “Emerging role of Toll-like receptors in the control of pain and itch,” Neuroscience Bulletin, vol. 28, no. 2, pp. 131–144, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. Y.-S. Wang, Y.-Y. Li, L.-H. Wang et al., “Tanshinone IIA attenuates chronic pancreatitis- induced pain in rats via downregulation of HMGB1 and TRL4 expression in the spinal cord,” Pain Physician, vol. 18, no. 4, pp. E615–E628, 2015. View at Google Scholar · View at Scopus
  88. L. Nicotra, L. C. Loram, L. R. Watkins, and M. R. Hutchinson, “Toll-like receptors in chronic pain,” Experimental Neurology, vol. 234, no. 2, pp. 316–329, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. D. Kim, A. K. Myung, I.-H. Cho et al., “A critical role of toll-like receptor 2 in nerve injury-induced spinal cord glial cell activation and pain hypersensitivity,” The Journal of Biological Chemistry, vol. 282, no. 20, pp. 14975–14983, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. L. Cao, F. Y. Tanga, and J. A. DeLeo, “The contributing role of CD14 in toll-like receptor 4 dependent neuropathic pain,” Neuroscience, vol. 158, no. 2, pp. 896–903, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. J. Qi, K. Buzas, H. Fan et al., “Painful pathways induced by TLR stimulation of dorsal root ganglion neurons,” Journal of Immunology, vol. 186, no. 11, pp. 6417–6426, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Schiraldi, A. Raucci, L. M. Muñoz et al., “HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4,” The Journal of Experimental Medicine, vol. 209, no. 3, pp. 551–563, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. K. Sakamoto, A. Mizuta, K. Fujimura et al., “High-mobility group Box-1 is involved in NMDA-induced retinal injury the in rat retina,” Experimental Eye Research, vol. 137, pp. 63–70, 2015. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Pedrazzi, M. Averna, B. Sparatore et al., “Potentiation of NMDA receptor-dependent cell responses by extracellular high mobility group box 1 protein,” PLoS ONE, vol. 7, no. 8, Article ID e44518, 2012. View at Publisher · View at Google Scholar · View at Scopus
  95. P. Schestatsky, L. Vidor, P. B. Winckler, T. G. de Araújo, and W. Caumo, “Promising treatments for neuropathic pain,” Arquivos de Neuro-Psiquiatria, vol. 72, no. 11, pp. 881–888, 2014. View at Publisher · View at Google Scholar · View at Scopus